G16.4 Kilder

Legemiddelanalyser, rusmiddelanalyser og farmakogenetiske analyser

1. Norsk forening for klinisk farmakologi Dnl. 2017 [cited 2017 09.07.2017] http://farmakologiportalen.no

2. Helsedirektoratet. Nasjonal faglig retningslinje for bruk av antibiotika i sykehus 2013

3. Sakshaug S, Strøm, H., Berg, C., Blix, H.S., Litleskare, I., Granum, T. Legemiddelforbruket i Norge 2012-2016,rapport mars 2017: Folkehelseinstituttet; 2017

4. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2017.

5. Reimers A, Berg JA, Burns ML, Landmark CJ. Harmonised reference ranges for antiepileptic drugs. Tidsskrift for den Norske legeforening. 2017;137(12-13):864-5.

6. Helland A, Berg JA, Gustavsen I, Nordal K, Hilberg T, Aronsen L, et al. Serum concentration measurements of addictive drugs. Tidsskrift for den Norske legeforening 2016;136(5):400-2

7. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clinical pharmacology and therapeutics. 2012;92(4):414-7

8. Klinisk farmakologi R, Oslo Universitetssykehus. [cited 2017 10.08 http://anx.no/kontakt-oss

9. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European heart journal. 2013;34(28):2159-219

10. Berra E, Azizi M, Capron A, Hoieggen A, Rabbia F, Kjeldsen SE, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension (Dallas, Tex : 1979). 2016;68(2):297-306

11. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. Journal of the American College of Cardiology. 2014;63(8):834-5

12. Edvardsen F, Oien CM, Helland A. Serum concentration monitoring of antihypertensive drugs in treatment resistant hypertension. Tidsskrift for den Norske legeforening 2016;136(18):1514-5

13. Owusu Obeng A, Hamadeh I, Smith M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy. 2017;37(9):1105-21

14. Douxfils J, Gosselin RC. Laboratory Assessment of Direct Oral Anticoagulants. Seminars in thrombosis and hemostasis. 2017;43(3):277-90

15. Lundgaard H, Dyrkorn R, Stokes CL, Molden E, Spigset O. Safer treatment with serum concentration monitoring of the new anticoagulants? Tidsskrift for den Norske legeforening 2016;136(18):1556-60

16. Solhaug V, Molden E. Genetically determined variation in bioactivation of tamoxifen and clopidogrel. Tidsskrift for den Norske legeforening. 2016;136(5):434-6

17. Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, et al. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. Journal of clinical psychopharmacology. 2016;36(4):355-71

18. Foundation NK. https://www.kidney.org/professionals/kdoqi/gfr_calculator.

19. Danmarks Apotekerforening DADL, Dansk Lægemiddel Information A/S og Institut for Rationel Farmakoterapi. 2017 [cited 09.08.2017]

20. interaksjoner.azurewebsites.net/

21. Bakke E, Bogstrand ST, Normann PT, Ekeberg O, Bachs L. Influence of alcohol and other substances of abuse at the time of injury among patients in a Norwegian emergency department. BMC emergency medicine. 2016;16(1):20

22. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Critical care (London, England). 2012;16(4):R136

23. Aakerøy R et al. Nye markører for påvisning av alkoholbruk. Tidsskr Nor Legeforen 2016;136(19):1643-7 

24. Schjøtt, J. Ultrakort om biologiske legemidler, Norsk Farmaceutisk Tidsskrift, 2017, 24-25. 

25. Klaveness, J. Biologiske legemidler og biotilsvarnde legemidler, Norsk Farmaceutisk Tidsskrift, 2008, 22-29. 

26. Bergan S og Bolstad, N: Persontilpasset behandling med biologiske legemidler, Norsk Farmaceutisk Tidsskrift, 2018, 40-43. 

27. Lundin, KEA og Goll, GL. Biologisk behandling innen gastroenterologi og revmatologi, Indremedisineren, 2016, 3, 10-13. 

28. Frost, J et al, 2019, Nye anbefalinger ved serumkosentrasjonsmålinger av sentralstimulerende legemidler, Tidsskr Nor Legeforen 2019 doi: 10.4045/tidsskr.19.0385 

29. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring